<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04897542</url>
  </required_header>
  <id_info>
    <org_study_id>FirstAHFujian8</org_study_id>
    <nct_id>NCT04897542</nct_id>
  </id_info>
  <brief_title>Gallium-68 NODAGA-JR11 PECT/CT in Neuroendocrine Tumors</brief_title>
  <official_title>A Prospective Study to Evaluate the Lesion Detection Ability of Gallium-68 NODAGA-JR11 for the Diagnostic Imaging of Metastatic, Well-differentiated Neuroendocrine Tumors Using PET/CT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>First Affiliated Hospital of Fujian Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>First Affiliated Hospital of Fujian Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      NODAGA-JR11 is a novel somatostatin receptor antagonist, while Gallium-68 DOTATATE is a&#xD;
      typical somatostatin receptor agonist. This study is to evaluate the lesion detection ability&#xD;
      of Gallium-68 NODAGA-JR11 for the diagnostic imaging of metastatic, well-differentiated&#xD;
      neuroendocrine tumors using positron emission tomography / computed tomography (PET/CT).&#xD;
&#xD;
      The results will be compared between antagonist Gallium-68 NODAGA-JR11 and agonist Gallium-68&#xD;
      DOTATATE in the same group of patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with histologically confirmed metastatic, well-differentiated neuroendocrine tumors&#xD;
      will be recruited in this study.&#xD;
&#xD;
      Each patient received an intravenous injection of 68Ga-DOTATATE (40ug/150-200MBq) on the&#xD;
      first day and 68Ga-NODAGA-JR11 (40ug/150-200MBq) on the second day. Whole-body PET/CT scans&#xD;
      were performed at 40-60 min after injection on the same scanner. Physiologic normal-organ&#xD;
      uptake, lesion numbers, and lesion uptake were compared.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2023</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Standard uptake value (SUV)</measure>
    <time_frame>From right after tracer injection to 2-hours post-injection</time_frame>
    <description>Determination of SUV for detected lesions and discernible organs of 68Ga-NODAGA-JR11 and 68Ga-DOTATATE scan.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lesion numbers</measure>
    <time_frame>From right after tracer injection to 2-hours post-injection</time_frame>
    <description>Determination of lesion numbers of 68Ga-NODAGA-JR11 and 68Ga-DOTATATE scan.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Neuroendocrine Tumors</condition>
  <arm_group>
    <arm_group_label>Patients will undergo a Gallium-68 NODAGA-JR11 PET/CT as well as a Gallium-68 DOTATATE PET/CT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each patient receive a single intravenous injection of Gallium-68 DOTATATE (40ug/150-200MBq) PET/CT, and undergo PET/CT scan at 40-60 min post-injection.&#xD;
All patients have to do a Gallium-68 NODAGA-JR11 PET/CT scan (40ug/150-200MBq, 40-60 min post-injection) for comparison on the next day of DOTATATE scan.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gallium-68 NODAGA-JR11</intervention_name>
    <description>Each patient receive a single intravenous injection of Gallium-68 NODAGA-JR11 (40ug/150-200MBq) PET/CT, and undergo PET/CT scan at 40-60 min post-injection.</description>
    <arm_group_label>Patients will undergo a Gallium-68 NODAGA-JR11 PET/CT as well as a Gallium-68 DOTATATE PET/CT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  • Written informed consent.&#xD;
&#xD;
               -  Patients of either gender, aged ≥ 18 years.&#xD;
&#xD;
               -  Histologically confirmed diagnosis of Metastatic, well-differentiated&#xD;
                  neuroendocrine tumor.&#xD;
&#xD;
               -  A diagnostic computed tomography (CT) or magnetic resonance imaging (MRI) of the&#xD;
                  tumor region within the previous 6 months prior to dosing day is available.&#xD;
&#xD;
               -  At least 1 measurable lesion based on RECIST v1.1.&#xD;
&#xD;
               -  Blood test results as follows (White blood cell: ≥ 3*10^9/L, Hemoglobin:&#xD;
&#xD;
                  ≥ 8.0 g/dL, Platelets: ≥ 50x10^9/L, Alanine aminotransferase / Aspartate&#xD;
                  aminotransferase / Alkaline phosphatase: ≤ 5 times upper limit od normal (ULN),&#xD;
                  Bilirubin: ≤ 3 times ULN)&#xD;
&#xD;
               -  Serum creatinine: within normal limits or &lt; 120 μmol/L for patients aged 60 years&#xD;
                  or older.&#xD;
&#xD;
               -  Calculated Glomerular filtration rate (GFR) ≥ 45 mL/min.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  • Known hypersensitivity to Gallium-68, to NODAGA, to JR11, to TATE or to any of the&#xD;
             excipients of Gallium-68 NODAGA-JR11 or Gallium-68 DOTATATE.&#xD;
&#xD;
               -  Presence of active infection at screening or history of serious infection within&#xD;
                  the previous 6 weeks.&#xD;
&#xD;
               -  Therapeutic use of any somatostatin analog, including long-acting Sandostatin&#xD;
                  (within 28 days) and short-acting Sandostatin (within 2 days) prior to study&#xD;
                  imaging. If a patient is on long-acting Sandostatina, then a wash-out phase of 28&#xD;
                  days is required before the injection of the study drug. If a patient is on&#xD;
                  short-acting Sandostatin, then a wash-out phase of 2 days is required before the&#xD;
                  injection of the study drug.&#xD;
&#xD;
               -  Any neuroendocrine tumor-specific treatment between antagonist and agonist scans.&#xD;
&#xD;
               -  Prior or planned administration of a radiopharmaceutical within 8 half-lives of&#xD;
                  the radionuclide used on such radiopharmaceutical including at any time during&#xD;
                  the current study.&#xD;
&#xD;
               -  Pregnant or breast-feeding women.&#xD;
&#xD;
               -  Current history of any malignancy other than neuroendocrine tumor; patients with&#xD;
                  a secondary tumor in remission of &gt; 5 years can be included.&#xD;
&#xD;
               -  Any mental condition rendering the patient unable to understand the nature, scope&#xD;
                  and possible consequences of the study, and/or evidence of an uncooperative&#xD;
                  attitude.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Weibing Miao, MD</last_name>
    <phone>86-0591-87981618</phone>
    <email>miaoweibing@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shaobo Yao, MD</last_name>
    <phone>86-0591-87981619</phone>
    <email>yaoshaobo008@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li Huo, MD</last_name>
      <phone>13910801986</phone>
      <email>huoli@pumch.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Fujian Medical University</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weibing Miao, MD</last_name>
      <phone>059187981618</phone>
      <email>miaoweibing@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Shaobo Yao, MD</last_name>
      <phone>059187981619</phone>
      <email>yaoshaobo008@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>May 18, 2021</study_first_submitted>
  <study_first_submitted_qc>May 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 21, 2021</study_first_posted>
  <last_update_submitted>July 13, 2021</last_update_submitted>
  <last_update_submitted_qc>July 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>First Affiliated Hospital of Fujian Medical University</investigator_affiliation>
    <investigator_full_name>Weibing Miao, PhD</investigator_full_name>
    <investigator_title>Director, Department of Nuclear Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroendocrine Tumors</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

